News, Events & Resources
There’s a lot happening at Melinta. We are the company of the moment and enterprise of the future. Join us in realizing our vision — this is our story, and it’s going to be legendary.
Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta’s Portfolio of Commercial and Investigational Stage Products
Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, ten scientific presentations with data focused on Melinta’s portfolio of commercial and investigational stage products to be shared at Infectious Disease Week (IDWeek) 2024, Oct. 16-19, 2024, in Los Angeles, Californi
Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.
November 9, 2023 Press Release Parsippany, N.J., and Malvern, PA -- November 9, 2023 — Melinta Therapeutics LLC (“Melinta”) and Venatorx Pharmaceuticals, Inc. (“Venatorx”), today announced that
Melinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023
October 11, 2023Press Release PARSIPPANY, N.J.–Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses,
Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO™ (rezafungin for injection)
October 2, 2023Press Release REZZAYO receives product-specific J-Code and is granted NTAP PARSIPPANY, N.J., October 2, 2023 – Melinta Therapeutics (Melinta), a commercial-stage company providing